Bisphosphonates for Osteopenia in Postmenopausal Women - Reply

Kristine E. Ensrud, Carolyn J. Crandall

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)1096-1097
Number of pages2
JournalJAMA - Journal of the American Medical Association
Volume323
Issue number11
DOIs
StatePublished - Mar 17 2020
Externally publishedYes

Bibliographical note

Funding Information:
Author Affiliations: Washington University School of Medicine in St Louis, St Louis, Missouri (Goldberg); Esperion Therapeutics Inc, Ann Arbor, Michigan (Hanselman); Oregon Health & Science University, Portland (Duell). Corresponding Author: Anne Carol Goldberg, MD, Washington University School of Medicine in St Louis, 660 South Euclid, Campus Box 8127, St Louis, MO 63110 (agoldber@wustl.edu). Conflict of Interest Disclosures: Dr Goldberg reported receiving grants from Amgen, Amarin, Pfizer, Regeneron, Sanofi, Ionis, Novartis, and Merck and serving as a consultant for Esperion, Novartis, Akcea, Optum RX, 23andMe, Sanofi/Regeneron, and Merck. Mr Hanselman reported receiving salary, personal fees, stock, and stock options from Esperion. Dr Duell reported receiving institutional research grants from Retrophin, Regeneron, and Regenxbio and serving as a consultant for Akcea, AstraZeneca, Esperion, Retrophin, Regeneron, and Regenxbio.

PubMed: MeSH publication types

  • Letter
  • Comment

Cite this